News - Greater Bay Area International Clinical Trial Institute

31.07.2025

GBAICTI Engaged With About 100 Industry Representatives to Enhance Hong Kong's Clinical Research Development

At a sharing session hosted by the Hospital Authority, the Greater Bay Area International Clinical Trial Institute (GBAICTI) engaged in-depth with around 100 industry representatives from over 30 companies to discuss enhancement measures and the future development of clinical trials in Hong Kong.

29.07.2025

GBAICTI, Bay Trial and Immuno Cure Signed Tripartite MOU to Strengthen GBA Clinical Research Collaboration

Greater Bay Area International Clinical Trial Institute, Greater Bay Area International Clinical Trials Center of Shenzhen and Immuno Cure BioTech signed a tripartite Memorandum of Understanding on July 29, 2025.

29.07.2025

GBAICTI and Bay Trial Signed a MOU to Strengthen Clinical Research Collaboration

GBAICTI and Bay Trial signed a Memorandum of Understanding on July 29, 2025 to strengthen collaboration between Shenzhen and Hong Kong in the field of clinical research.

09.07.2025

GBAICTI and Hong Kong Genome Institute Explore Partnership in Genomic Medicine

Greater Bay Area International Clinical Trial Institute (GBAICTI) met with Hong Kong Genome Institute (HKGI) to explore collaborative opportunities in genomic medicine.

26.06.2025

Delegation Visit of NMPA GBA Center

On June 26, 2025, a delegation from the GBA Center for Medical Device Evaluation and Inspection of the National Medical Products Administration (NMPA) visited GBAICTI to learn about the its facility, ongoing work, and future development plans.

21.05.2025

GBAICTI signed MOU on clinical trial collaboration with HKU and CUHK medical faculties

Greater Bay Area International Clinical Trial Institute held a collaboration meeting with the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) and the Faculty of Medicine of the Chinese University of Hong Kong (CU Medicine) to have an in-depth exchange on advancing clinical trial collaboration on May 21, 2025. The three parties signed a Memorandum of Understanding (MOU) on clinical trial collaboration after the meeting.